Phase 1 study of VX-440, a next-generation corrector alone and in combination with VX-661/ivacaftor in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2016
At a glance
- Drugs VX 440 (Primary) ; Ivacaftor/tezacaftor
- Indications Cystic fibrosis
- Focus Adverse reactions
- 27 Apr 2016 Status changed from not yet recruiting to recruiting, as reported by Vertex media release.
- 30 Oct 2015 New trial record
- 09 Oct 2015 According to a Vertex Pharmaceutical media release, this trial will begin in November 2015.